Abivax CEO says $920M raise lets it launch its bowel disease drug in the U.S. solo
Culture Index
Score Breakdown
Relevance
9/25
Freshness
24/25
Authority
18/20
Brand Signal
6/15
Depth
2/15
5-Axis Cultural Radar
The French biotech plans to use proceeds to commercialize obefazimod in the U.S. through 2029, CEO Marc de Garidel told CNBC
